Peptides DB
Research-centric peptide and protocol reference hub

Octreotide record · updated 6h ago

Healing & recoveryMetabolic & appetiteGrade A · human clinicalResearch use only
All 31 studiesJump to the evidenceCompare
What is Octreotide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: SSTR2 agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Octreotide sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 106 registered trials. It describes the research record, not a recommendation.

Identity
NameOctreotide
Chain length—
Molecular weight1,019.2 Da
FormulaC49H66N10O10S2
Structure typeNot established
ClassHealing
Research levelWell Studied
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 448601. No verified residue count for this compound.

Pharmacology
MechanismSSTR2 agonist
RouteSubcutaneous injection
Half-life~2 hours
Time to peak30 min
Duration6–12 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 19, 2026. How this works →
Research stats
Total studies31
Human / animal / cellular24 / 2 / 3
Highest trial phasePreclinical
Years covered1993–2026
Latest study9d ago
Publication history
19932026
Research funding
564 NIH projects · $21.4M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports6,316
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

31 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Activation of the dopamine D2 receptor enhances colonic motility via disinhibition of somatostatinergic signalling in rodents.
FindingNot reported in abstract.
Animal2026Full text read0.70
Metastatic proinsulin-secreting tumor: a rare cause of persistent hypoglycemia.
FindingNot reported in abstract.
Human2023Full text read0.80
The Extent of Ligand-Receptor Interactions for Actively Targeted Nanoparticles as a Function of Ligand Density and Receptor Expression.
FindingNot reported in abstract.
In vitro2026Full text read0.70
Differential Somatostatin Sensitivity of Corticotropic and Somatotropic Responses Following Amino Acid Infusion.
FindingNot reported in abstract.
Human2026Full text read0.80
Lesion-level Quantitative Post-therapy SPECT/CT During <sup>177</sup>Lu-DOTATATE PRRT for NET Liver Metastases.
FindingLesion volume, kBq/ml max, and SUVmax significantly decreased from baseline to final evaluation (all p<0.01).
Human2023Full text read0.80
DOTATATE-PET in custom spheno-orbital implant design for meningiomas with orbital involvement: a case series.
FindingNot reported in abstract.
Human2026Full text read0.70
Octreotide Administration Methods in Sulfonylurea Poisoning: A Retrospective Chart Review.
FindingMedian post-octreotide hypoglycemic events were zero for bolus, 1.5 for infusion, and zero for subcutaneous groups.
Human2026Full text read0.80
Double emulsions enable in situ generation of permeation enhancers for oral delivery of macromolecules.
Finding∼4-fold increase in FD-4 permeability for the digested emulsions.
Animal2026Full text read0.80
Self-assembly of sodium caprate in simulated intestinal fluids and with a therapeutic peptide: A small-angle neutron scattering study.
FindingAggregation numbers approaching 18,000 in the presence of octreotide.
In vitro2026Full text read0.70
Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.
FindingNone of the 21 patients had documented shrinkage of the tumor mass.
Human1993Full text read0.80
Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man.
FindingNot reported in abstract.
Human1993Full text read0.80
Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly.
FindingGH mRNA in octreotide-treated adenomas was 4.2 +/- 1.8 (mean +/- SEM) in arbitrary units.
Human1994Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Octreotide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Octreotide is discussed should be drawn from it.